<DOC>
	<DOCNO>NCT01134107</DOCNO>
	<brief_summary>Patients continue use current insulin pump study . Patients receive insulin lispro insulin aspart study . One medication take 12 week medication 12 week . Neither patient study doctor know medication take time . The order two medication take determined chance .</brief_summary>
	<brief_title>Insulin Lispro 6 Days Versus Insulin Aspart 6 Days Pump Use</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Diagnosed type 1 diabetes ( World Health Organization criterion ) least 24 month Treated continuous subcutaneous insulin infusion ( CSII ) therapy previous 6 month Mean total daily insulin dose 3 day prior screen less equal 46 units/day use 300Unit reservoir , less equal 30 units/day use 200 unit reservoir , less equal 26 units/day use 180 unit reservoir Baseline body mass index ( BMI ) less equal 35.0 kilogram per meter square ( kg/m2 ) Baseline glycated hemoglobin A1c ( HbA1c ) 5 % 9 % Impaired renal function ( serum creatinine great equal 2.0 milligram per deciliter ( mg/dL ) ) Legal blindness Have episode 12 month prior screen hypoglycemic coma , seizure , disorientation Have hypoglycemia unawareness ( routinely asymptomatic blood glucose le 45 mg/dL [ 2.5 millimoles per liter ( mmol/L ) ] ) 12 month prior screen . Have emergency room visit hospitalization due poor glucose control 12 month prior screen . Have pumprelated infusion site abscess 12 month prior screen . Have multiple , clinically significant occlusion judge investigator . Have infection Staphylococcus aureus past 5 year Have one follow concomitant disease : presence clinically significant hematologic , oncologic , renal , cardiac , hepatic , gastrointestinal disease , serious disease consider investigator exclusionary . Participants malignancy basal cell squamous cell skin cancer yet treat , currently treat , diagnose less 5 year ago . Have blood transfusion severe blood loss within 3 month prior screen know hemoglobinopathy , hemolytic sickle cell anemia , traits hemoglobin abnormality know interfere HbA1c methodology . Are receive chronic systemic glucocorticoid therapy , receive therapy within 4 week precede screening . Have irregular sleep/wake cycle investigator 's opinion . Have know hypersensitivity allergy study insulins excipients Are breastfeed pregnant , intend become pregnant course study , sexually active woman childbearing potential actively practice birth control method determine investigator medically acceptable . Are currently enrol , discontinue within last 30 day clinical trial involve offlabel use investigational drug device , currently enrol type medical research scientifically medically compatible study . Are unwilling unable comply use data collection device directly record data participant .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>